Handbook of therapeutic antibodies
著者
書誌事項
Handbook of therapeutic antibodies
Wiley-VCH , John Wiley, distributor], c2007
- : set
- : set
- v. 1
- v. 2
- v. 3
大学図書館所蔵 件 / 全3件
-
v. 1491.85/D 93/10001638147,
v. 2491.85/D 93/20001638154, v. 3491.85/D 93/30001638162 -
該当する所蔵館はありません
- すべての絞り込み条件を解除する
注記
Includes bibliographical references and index
v. 1. Technologies -- v. 2. Emerging developments. -- v. 3. Approved therapeutics
内容説明・目次
内容説明
In this most comprehensive reference source for the development, production and therapeutic application of antibodies, Volume I contains general chapters presenting established technologies and clinical applications. Volume II provides a look at emerging technologies, new therapeutic concepts, and clinical studies. The third volume features detailed and specific information about each currently approved type of antibody, including the clinical data. A must-have resource for academic researchers, decision makers in industry and healthcare professionals in the clinic.
目次
Volume I: Technologies Foreword A Greeting from the Editor PART 0: INTRODUCTION Therapeutic Antibodies - From Past to Future PART I: SELECTING AND SHAPING THE ANTIBODY MOLECULE Selection strategies I: Monoclonal Antibodies Selection strategies II: Antibody Phage Display Selection strategies III: Transgenic Mice Bioinformatic Tools for Antibody Engineering Molecular Engineering I: Humanization Molecular Engineering II: Affinity Maturation Molecular Engineering III: Fc Engineering PART II: THE WAY INTO THE CLINIC Production and Downstream Processing Pharmaceutical Formulation and Clinical Application Immunogenicity of Antibody Therapeutics Regulatory Considerations Intellectual Property Issues Volume II: Emerging Developments PART III: BEYOND IGG: MODIFIED ANTIBODIES Immunoscintigraphy and Radioimmunotherapy Bispecific Antibodies Immunotoxins / Targeted RNases PART IV: EMERGING CONCEPTS Automation of Selection and Engineering Emerging Technologies for Antibody Selection Emerging Alternative Production Systems Non-Antibody Scaffolds Emerging Therapeutic Concepts I: ADEPT Emerging Therapeutic Concepts II: Nanotechnology Emerging Therapeutic Concepts III:Cell-bound antibodies Emerging Therapeutic Concepts IV:Anti-idiotypic Antibodies PART V: ONGOING CLINICAL STUDIES: Antibodies in Phase I/II/III: Cancer Therapy Antibodies in Phase I/II/III: Targeting TNF VOLUME III: APPROVED THERAPEUTICS Adalimumab (Humira) Alemtuzumab (Mabcampath) Bevacizumab (Avastin) Cetuximab (Erbitux) Efalizumab (Raptiva) Fanolesomab/Technetium99m (Neutrospec) Gemtuzumab Ozogamicin (Mylotarg) Infliximab (Remicade) Muromonab (Orthoclone) Natalizumab (Tysabri) Omalizumab (Xolair) Palivizumab (Synagis) Rituximab (Rituxan) Trastuzumab (Herceptin) Overview: Abciximab, Arcitumomab, Basiliximab, Capromab, Cotara, Daclizumab, Edrecolomab, Ibritumomab, Igovomab, Nofetumomab, Satumomab, Sulesomab, Tositumomab and Votumumab
「Nielsen BookData」 より